Sequoia Financial Advisors LLC Takes Position in ICU Medical, Inc. (NASDAQ:ICUI)

Sequoia Financial Advisors LLC bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 2,424 shares of the medical instruments supplier’s stock, valued at approximately $442,000.

Several other large investors have also recently bought and sold shares of the stock. Xponance Inc. lifted its position in shares of ICU Medical by 6.0% in the second quarter. Xponance Inc. now owns 1,977 shares of the medical instruments supplier’s stock valued at $235,000 after buying an additional 112 shares during the last quarter. CWM LLC increased its stake in shares of ICU Medical by 18.5% during the second quarter. CWM LLC now owns 767 shares of the medical instruments supplier’s stock worth $91,000 after purchasing an additional 120 shares during the period. Hexagon Capital Partners LLC lifted its holdings in ICU Medical by 162.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of ICU Medical by 46.4% in the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 173 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of ICU Medical by 7.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,576 shares of the medical instruments supplier’s stock valued at $257,000 after buying an additional 187 shares in the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $18,665,666.78. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at $18,665,666.78. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,552 shares of company stock worth $6,679,322. 6.70% of the stock is owned by insiders.

ICU Medical Price Performance

Shares of ICUI opened at $175.56 on Monday. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. The business’s fifty day moving average is $172.59 and its 200 day moving average is $135.13. ICU Medical, Inc. has a 12-month low of $78.28 and a 12-month high of $188.53. The stock has a market cap of $4.28 billion, a P/E ratio of -71.66 and a beta of 0.66.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. The business had revenue of $596.50 million during the quarter, compared to the consensus estimate of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The company’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.58 EPS. Sell-side analysts anticipate that ICU Medical, Inc. will post 3.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on ICUI shares. KeyCorp increased their target price on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Jefferies Financial Group assumed coverage on ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective on the stock. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Thursday, October 10th. Finally, Raymond James raised their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $170.25.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.